Posology : מינונים

4.2    Posology and method of administration

Unless otherwise prescribed, Uromitexan 400 mg is usually administered by i.v. injection in adults at a dose of 20 % of the respective oxazaphosphorine dose, at times 0 (administration of oxazaphosphorine), 4 hours and 8 hours.

Example of administration of Uromitexan 400 mg concurrently with oxazaphosphorine injection:
Hours                  0                    4                      8
(Time)                 (08:00 p.m.)         (12:00 p.m.)           (4:00 p.m.) Oxazaphosphorine              40 mg/kg body weight               _                      _
Dose
Uromitexan 400mg              8 mg/kg              8 mg/kg                8 mg/kg body weight          body weight            body weight
Dose

Therapeutic experience with children has shown that in individual cases it is advisable to administer Uromitexan 400 mg more frequently (e. g. up to six times) and at shorter intervals (e. g. of 3 hours).

If ifosfamide (Holoxan®) is given by continuous infusion it is advisable to add Uromitexan 400 mg after a bolus injection (20 %) at time 0 (start of infusion, hour,"0") at dosages of up to 100 % of the respective dose of continuous infusion ifosfamide. The uroprotectant effect should be maintained for another 6 to 12 hours after completion of the ifosfamide infusion using up to 50 % of the respective ifosfamide dose.


Example of administration of Uromitexan 400 mg concurrently with a 24-hour infusion of ifosfamide:
Hours                          0                               24      30     36 2
Ifosfamide infusion            5 g/m body surface area
( 125 mg/kg body weight)
Uromitexan 400 mg              1 g/m2 body surface area
Bolus                          ( 25 mg/kg body weight)
Uromitexan 400 mg              up to 5 g/m2 body surface       up to 2.5 g/m2 Infusion                       area                            Body surface area ( 125 mg/kg body weight)       ( 62.5 mg/kg body weight)
Addition to ifosfamide infusion

Method of administration
Intravenous use. Check the medicinal product for visible particles and discoloration prior to use.
Do not use solutions that are discolored or hazy or contain visible particles.
The duration of use of Uromitexan® 400 mg depends on the duration of oxazaphosphorine treatment.